Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943959 | 1.00 | TACR1 (0.62) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL385325 | 1.00 | TACR1 (0.62) | TACR1LMNAACHESIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL10382846 | 0.98 | LMNA (0.64) | TACR1LMNAACHESIGMAR1GRIN1 | |
| Iodide SCHEMBL8816299 | 0.98 | TACR1 (0.61) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL20274753 | 0.86 | ACHE (0.63) | TACR1ACHESIGMAR1MC4RBCHE | |
| SCHEMBL9466471 | 0.84 | ACHE (0.54) | TACR1LMNAACHESIGMAR1 | |
| SCHEMBL9379752 | 0.83 | ACHE (0.50) | TACR1LMNAACHESIGMAR1MC4R | |
| SCHEMBL6230149 | 0.82 | LMNA (0.46) | TACR1LMNAACHEBCHE | |
| SCHEMBL31193852 | 0.81 | TACR1 (0.59) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL1339508 | 0.81 | TACR1 (0.59) | TACR1LMNAACHESIGMAR1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 891 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954807-A | Method for preparing dihydrochloride of anticancer agent | 昂克希尔迪克斯有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-118580192-A | Preparation method of chiral intermediate of drug for treating ocular hypertension | 安徽峆一药业股份有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-114957100-B | Synthesis process of 1-benzyl-3-methyl-4-piperidone | 苏州诚和医药化学有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115010652-A | Synthesis process of piperidine derivative intermediate | 苏州诚和医药化学有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-114957100-A | Synthesis process of 1-benzyl-3-methyl-4-piperidone | 苏州诚和医药化学有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4644396-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | Visionpharma (Nantong) Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-118580192-B | Preparation method of chiral intermediate of drug for treating ocular hypertension | 安徽峆一药业股份有限公司 | 2025-09-19 | — | — | CN | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-0106276-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4639522-A | HYPOTENSIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
| US-4584303-A | ANALGESICS | THE BOC GROUP, INC. (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0160422-A1 | N-Aryl-N-(4-Piperidinyl)amides and pharmaceutical compositions and methods employing such compounds | Anaquest, Inc. (US) | 1985-11-06 | — | — | EP | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
| US-4481360-A | 4H-1,2,4-Triazol-3-yl compounds | THE UPJOHN COMPANY (US) | 1984-11-06 | — | — | US | disclosed |
| EP-0106276-A2 | 1,4-Dihydropyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-04-25 | — | — | EP | disclosed |
| EP-0092391-A2 | Novel piperidine derivatives and pharmaceutical compositions containing same | KYOWA HAKKO KOGYO CO., LTD (JP) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | TACR1 2886/4885LMNA 1902/4885ACHE 4588/4885 |
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | BCL6, BCL6B, BCL9L | TACR1 1277/4885LMNA 983/4885ACHE 4882/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | TACR1 4881/4885LMNA 1711/4885ACHE 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.